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Background: Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in
TSC1 and TSC2. Conventional DNA diagnostic screens identify a TSC1 or TSC2 mutation in 75 - 90% of individuals
categorised with definite TSC. The remaining individuals either have a mutation that is undetectable using conventional
methods, or possibly a mutation in another as yet unidentified gene.
Methods: Here we apply a targeted Next Generation Sequencing (NGS) approach to screen the complete TSC1 and
TSC2 genomic loci in 7 individuals fulfilling the clinical diagnostic criteria for definite TSC in whom no TSC1 or TSC2
mutations were identified using conventional screening methods.
Results: We identified and confirmed pathogenic mutations in 3 individuals. In the remaining individuals we identified
variants of uncertain clinical significance. The identified variants included mosaic changes, changes located deep in
intronic sequences and changes affecting promoter regions that would not have been identified using exon-only
based analyses.
Conclusions: Targeted NGS of the TSC1 and TSC2 loci is a suitable method to increase the yield of mutations identified
in the TSC patient population.
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Tuberous sclerosis complex (TSC) is an autosomal dom-
inant disorder characterised by the development of
hamartomas in a variety of organs and tissues, including
the brain, skin and kidneys [1]. Penetrance is high but
the phenotypic manifestations of the disease are variable.
Some individuals show only minor signs of disease,
sometimes without clear symptoms. Others are severely
affected from an early age and at multiple sites through-
out the body. Approximately two-thirds of cases are
sporadic.
In 75 - 90% of tested individuals categorised as definite
TSC according to the 1998 Consensus Conference Clin-
ical Diagnostic Criteria [2], a mutation in either TSC1 on* Correspondence: m.nellist@erasmusmc.nl
1Department of Clinical Genetics, Ee-2426, Erasmus Medical Center,
Wytemaweg 80, 3015 Rotterdam, CN, The Netherlands
Full list of author information is available at the end of the article
© 2015 Nellist et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.chromosome 9q34 or TSC2 on chromosome 16p13.3 is
identified [3]. TSC1 and TSC2 are tumour suppressor
genes that encode respectively hamartin (TSC1; 130 kDa)
and tuberin (TSC2; 200 kDa). TSC1 and TSC2 form a
stable protein complex that in response to diverse cellular
signals, notably growth factors and the availability of
energy, regulates the activity of the mechanistic target
of rapamycin (mTOR) complex 1 (TORC1) [4]. TORC1
is a central regulator of cell metabolism, controlling
protein, lipid and pyrimidine synthesis and autophagy
[5]. Elucidation of the role of the TSC1-TSC2 complex
in TORC1 signaling has provided new insights into
basic cell biology and, importantly for TSC patients,
has led to the development of promising new therapies
based on the use of specific TORC1 inhibitors such as
rapamycin and its derivatives [6].
Early diagnosis of TSC facilitates genetic counselling,
therapeutic intervention and disease monitoring [1].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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means that establishing a definite clinical diagnosis of
TSC can be challenging, particularly for young patients.
The recommendation of the 2013 International TSC
Consensus Conference was that the identification of a
clearly pathogenic TSC1 or TSC2 mutation should be
sufficient to make a diagnosis of TSC, even in the ab-
sence of clear clinical signs [1]. Unfortunately, despite
the remarkable progress in TSC research over the last
decade, conventional molecular testing fails to identify a
pathogenic TSC1 or TSC2 mutation in 10 - 25% of indi-
viduals with TSC. These patients are usually referred to
as TSC no mutation identified (NMI) [7].
In addition to technical failures, there are several pos-
sible reasons for the inability to detect mutations in TSC
NMI individuals. First, mutations to other as yet uniden-
tified genes may cause TSC. Second, constitutional epi-
genetic changes, such as promoter methylation causing
transcriptional silencing [8], may occur. Third, specific
classes of mutation, such as mosaic mutations and muta-
tions in intronic and regulatory regions may not be de-
tectable using conventional tests. The development of
massively parallel sequencing methods, so-called Next
Generation Sequencing (NGS) technology, has made it
possible to apply new approaches to mutation detection
[9], and has the potential to increase the yield of muta-
tions identified in individuals with TSC. High-yield
mutation detection methods would help to reduce un-
certainty and anxiety in the significant proportion of in-
dividuals and families for whom existing diagnostic
methods are not informative. NGS strategies have been
applied to TSC NMI individuals. For example, in a series
of 38 TSC NMI individuals, 2 (6%) mosaic mutations
and 5 (13%) heterozygous mutations that had been
missed by other mutation detection methods were iden-
tified using exon-specific ultra-deep sequencing [10].
One limitation of this approach was that it was restricted
to the exons and adjacent intronic sequences of TSC1
and TSC2. Mutations deep within introns or in pro-
moter and other regulatory sequences could not be
detected.
Here we present the results of a pilot study using tar-
geted NGS to investigate the DNA of 7 individuals with
definite, clinically confirmed TSC in whom extensive
conventional mutation analysis had failed to identify a
pathogenic mutation. In addition to providing these in-
dividuals with increased certainty over their mutation
status, exclusion of the existence of pathogenic TSC1 or
TSC2 mutations in these individuals would help identify
a cohort for the identification of the putative TSC3
locus. We employed the HaloPlex targeted capture
method [11]. This technique relies on the specific cap-
ture of restriction fragments from the locus of interest
followed by amplification and sequencing of the capturedfragments. Haloplex has the advantage of working with
a defined set of fragments, that simplifies data analysis
[12]. In 3 individuals we identified and confirmed a TSC2
mutation that had been missed, or was undetectable, using
conventional exon-based screening approaches. In the
remaining individuals we identified novel variants from
either the TSC1 and TSC2 loci. However, the clinical
significance of these variants is not yet certain. Our
pilot study indicates that targeted NGS will increase the




Clinical information on the 7 index cases and available
family members was collected. In each case the proband
fulfilled the diagnostic criteria for definite TSC [1]
(Table 1). All the individuals included in the study pro-
vided informed consent for mutation analysis of TSC1
and TSC2. In each case conventional molecular testing
(see below) was negative [13], although multiple neutral
TSC1 and TSC2 variants were identified in several indi-
viduals (Table 2). The study was performed as part of
our diagnostic service and was therefore exempt from
the Erasmus MC ethics committee approval.
DNA and RNA isolation
DNA extraction from peripheral blood was performed
according to standard protocols. DNA quality and con-
centration were checked with the Quant-iT PicoGreen
dsDNA Kit (Invitrogen Corporation, Carlsbad, CA,
USA). DNA and RNA isolation from skin fibroblasts in
culture was performed according to standard protocols.
Cells were cultured under standard conditions, and in
the presence of cycloheximide, to inhibit nonsense-
mediated mRNA decay.
Conventional TSC1 and TSC2 molecular testing
Conventional mutation analysis of TSC1 and TSC2 was
performed as described previously [12,13]. For the
detection of single nucleotide changes, denaturing gel
electrophoresis (DGGE), single-strand conformation
polymorphism (SSCP) and/or direct sequence analysis
of all coding exons and exon/intron boundaries was
performed. For the detection of large rearrangements,
Southern blotting, fluorescence in situ hybridisation
(FISH), quantitative (Q)-PCR and/or multiplex ligation-
dependent probe amplification (MLPA) were performed.
HaloPlex design
We designed a HaloPlex custom capture array using the
SureDesign software provided by Agilent Technologies
(Santa Clara, USA). The design was tailored to the 150
base-pair (bp) paired-end sequencing technology from
Table 1 Clinical overview of the TSC NMI individuals
Individual Age Brain Skin Other Family members
I 13 yr; Dx0 CT HM CR Parents (healthy)
II 13 yr; Dx2 SEN, CT HM CR, AML Parents and sibling (mother and sibling affected)
III 14 yr; Dx4 SEN, CT FA, HM AML, RC, CR Parents (healthy)
IV 9 yr; Dx8 SEGA, SEN, CT FA, HM AML, CR, RP Parents (healthy; not investigated clinically)
V 8 yr; Dx3 SEN, CT HM AML Parents (healthy)
VI 9 yr; Dx1 SEN, CT FA, HM AML, CR Parents (healthy)
VII 46 yr; Dx15 WMA FA, HM TE Child (affected)
Age and age at diagnosis (Dx) and the affection status of first degree relatives of the index cases (I - VII) are indicated, as well as the brain, skin and other clinical
findings in the index cases. AML: angiomyolipoma; CR: cardiac rhabdomyoma; CT: cortical tuber; FA: facial angiofibroma; HM: hypomelanotic macule; RC: renal
cysts; RP: retinal phakoma; SEGA: subependymal giant cell astrocytoma; SEN: subependymal nodule; SP: shagreen patch; TE: tooth enamel defect; UF: ungual
fibroma; WMA: white matter abnormalities.
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encompassing the TSC1 locus (GRCh37/hg19 chromo-
some 9q34: g.135825221 - 135760595; bases covered:
63855 bp (98.8%); bases not covered: 741 bp) and 52228
bases encompassing the TSC2 locus (GRCh37/hg19
chromosome 16p13.3: g.2087907 - 2140135; bases cov-
ered: 50997 bp (97.6%); bases not covered: 1231 bp).
The TSC1 and TSC2 loci were digested into respectively
1338 and 1074 restriction fragments for capture and
amplification (size range 50–450 bp). Amplicons could
not be designed for 741 bases (1.1%) of the TSC1 locus
and for 1231 bases (2.4%) of the TSC2 locus (Additional
file 1: Table S1). To allow identification of mutations af-
fecting promoters and other 5′ regulatory elements, ~10
kilobases (kb) upstream of TSC1 and TSC2 were cap-
tured. In addition, ~10 kb downstream of the TSC1 3′-
UTR was captured to allow the detection of mutations
affecting downstream regulatory sequences. For the
TSC2 locus, downstream sequences were not included.
This region, encompassing the 3′ end of the adjacent
PKD1 gene, includes sequences that are repeated at high
homology elsewhere on chromosome 16 [14] and were
considered likely to complicate target capture and data
analysis. Furthermore, mutations affecting PKD1 as well
as TSC2 usually result in a distinct, severe renal phenotype
[15]. None of the patients included in our study had se-
vere renal involvement from an early age (Table 1).
Sequence data generation and analysis
Sequence data was generated with an Illumina MiSeq se-
quencer, using the paired-end 150 bp sequencing proto-
col and the MiSeq reagent kit V2. Prior to alignment,
the TruSeq 3′ adapter sequences were trimmed from the
reads using custom in-house software that matches the
largest possible sub-sequence of the adapter to that of
the read and then trims the matching and downstream
sequence. The trimmed reads were subsequently aligned
to the human reference genome (build hg19) using the
Burrows-Wheeler alignment (BWA) tool [16] and custom-
designed in-house alignment software called NIMBUS(Brouwer et al., in preparation). Single nucleotide sub-
stitution (SNP) and insertion/deletion (InDel) variants
were called using two strategies. To identify germ-line
variants, the Genome Analysis Tool Kit (GATK) and
Unified Genotyper [17] were used. Variants were assessed
according to the depth of coverage (number of reads and
number of HaloPlex fragments containing the variant
base), the number of individuals with the same variant,
whether the variant corresponded to a known SNP and
whether the variant was likely to affect either the cod-
ing sequence or expression of TSC1 or TSC2. To call
mosaic variants, SAMtools mpileup [18] and in-house
software were used. We considered all variants called at
a minor allele frequency >10% and with at least 3 reads
representing an alternative allele. To compare the cover-
age per target fragment per individual we calculated
z-scores for all the sequenced fragments in the target
regions [19].
To investigate potential effects on splicing, the identified
variants were analysed with SpliceSiteFinder-like, Max-
EntScan, NNSPLICE, GeneSplicer and Human Splice
Finder in the ALAMUT version 2.3 software package
(Interactive Biosoftware, Rouen, France).
PCR-based confirmation of identified variants
Allele-specific PCR was performed according to a stand-
ard protocol (conditions and primer sequences available
on request). RT-PCR was performed on total RNA iso-
lated from untreated and cycloheximide-treated cultures
of human skin fibroblasts. Standard PCR and Sanger se-
quencing were performed as described previously [12]
(primer sequences available on request).
Results and discussion
HaloPlex custom capture of the TSC1 and TSC2 genomic
loci
The TSC1 and TSC2 loci of blood DNA samples from
7 clinically definite TSC patients were analysed. We
mapped the sequence reads using two different align-
ment tools: a standard BWA analysis [16] and NIMBUS,
Table 2 Overview of the “new” TSC1 and TSC2 variants
Individual I HaloPlex (% minor allele)
Validation (PCR-Sanger sequencing)
Index Father Mother
chr9 g.135804394A > G; TSC1 c.80-55 T > C (intron 3) +/− +/− +/− −/−
chr9 g.135798153C > T; TSC1 c.508 + 582G > A (intron 6) +/− +/− −/− +/−
chr9 g.135791383 T > C; TSC1 c.738-3539A > G (intron 8) +/− +/− −/− +/−
chr9 g.135765655 T > C; TSC1 c.*5967A > G (exon 23; 3′UTR) +/− +/− −/− +/−
chr 16 g.2108070C > A; TSC2 c.849-678C > A (intron 9) +/− +/− −/− +/−
chr 16 g.2119403C > T; TSC2 c.1717-1054C > T (intron 16) +/− +/− −/− +/−
chr 16 g.2124981C > G; TSC2 c.2545 + 591C > G (intron 22) +/− (20%) −/−* −/− −/−
chr 16 g.2125962C > T; TSC2 c.2639 + 69C > T (intron 23) +/− +/− −/− +/−
chr 16 g.2131815insC; TSC2 c.3814 + 19dup (intron 31) +/− (18%) −/−* −/− −/−
Individual II HaloPlex (% minor allele) Validation (PCR-Sanger sequencing)
Index Sibling Father Mother
chr9 g.135801283C > T; TSC1 c.211-157G > A (intron 4) +/− (31%) +/− +/− +/− −/−
chr9 g.135775735 T > C; TSC1 c.2625 + 367A > G (intron 20) +/− +/− +/− −/− +/−
chr 9 g.135775718insA (rs36000704); TSC1 c.2625 + 383dup (intron 20) +/− ? ? ? ?
chr 9 g.135775530 T > C (rs2284902); TSC1 c.2625 + 572 (intron 20) +/− +/− +/− +/− −/−
chr9 g.135775415dup (rs200047376); TSC1 c.2625 + 687dup (intron 20) +/− (35%) +/− +/− +/− −/−
chr9 g.135775427 T > C (rs6597584); TSC1 c.2625 + 675 T > G (intron 20) +/− +/− +/− +/− −/−
Individual III HaloPlex (% minor allele) Validation (alle-specific PCR)
Index Father Mother
chr16 g.2129165, rs45464800; TSC2 c.3099C > G (exon 16) +/− (9%) +/− −/− −/−
Individual IV HaloPlex Validation (PCR-Sanger sequencing)
Index Father Mother
chr16 g.2100489 T > A; TSC2 c.225 + 2 T > A (intron 3) +/− +/− −/− −/−
chr16 g.2102256del10, rs140492671; TSC2 c.226-1086del10 (intron 3) +/+ +/+ (ins Alu) +/− (ins Alu) +/+ (ins Alu)
Individual V HaloPlex Validation (PCR-Sanger sequencing)
Index Father Mother
chr9 g.135820146delACTCATA; TSC1 c.-15894_-15888del +/− +/− −/− +/−
chr9 g.135763459 T > A; 3′ TSC1 exon 23 +/− +/− −/− +/−
Individual VI HaloPlex (% minor allele) Validation (alle-specific PCR)
Index Father Mother
chr16 g.2127477G > A; TSC2 c.2838-122G > A (intron 25) +/− (12%) +/− −/− −/−
Individual VII HaloPlex (% minor allele) Validation (PCR-Sanger sequencing)
chr16 g.2101947C > T, rs139385485; TSC2 c.226-1396 T > C (intron 3) +/− (18%) +/−
chr16 g.2102256del10, rs140492671; TSC2 c.226-1086del10 (intron 3) +/− (10%) +/− (ins Alu)
chr16 g.2105289 T > C, rs77037371; TSC2 c.482-114 T > C (intron 5) +/− (70%) +/−
chr16 g.2105335C > G, rs2516734; TSC2 c.482-68C > G (intron 5) +/− (70%) +/−
chr16 g.2113125A > G; TSC2 c.1443 + 71A > G (intron 14) +/− +/−
chr16 g.2113464C > T; TSC2 c.1443 + 410C > T (intron 14) +/− +/−
chr16 g.2120785C > T; TSC2 c.1839 + 206C > T (intron 17) +/− +/−
chr16 g.2130697G > A; TSC2 c.3610 + 319G > A (intron 30) +/− +/−
Variants identified by HaloPlex custom capture NGS without an rs-number in dbSNP132 are listed per individual. The results of the subsequent PCR-Sanger
sequencing and/or allele-specific PCR validation are shown for the relevant individual and any available family members. Results for variants identified with a
skewed allelic ratio (minor allele detected in <40% or >60% of the sequence reads) are also shown. * indicates a discrepancy between the HaloPlex result and
the validation experiment. ? indicates that the nucleotide change identified by HaloPlex could not be confirmed by Sanger sequencing due to the presence of
polyA:T stretches. Pathogenic mutations are indicated in bold.
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preparation). A comparison of these two approaches is
shown in Figure 1. Using standard BWA we obtained an
average of 292487 reads per individual; using NIMBUS
we obtained an average of 297476 reads per individual
(Additional file 1: Table S2). For both aligners, the mean
coverage for the TSC1 and TSC2 loci was 96% and 92%
respectively at a read-depth >0. At a read-depth >10,
the mean coverage fell to 90% for TSC1 and 86% for
TSC2 using BWA, and 97% for TSC1 and 94% for
TSC2 using NIMBUS (Additional file 1: Table S2). At a
read-depth >100, mean coverage fell to 50% for both
loci using BWA, while with NIMBUS, on average, 79%
of both loci was covered (Figure 1). Detection of allelic
imbalances and mosaic mutations was relatively straight-
forward for these regions. All variants (see below, and
Additional file 1: Table S3), were detected by both ap-
proaches. Approximately 10% of the TSC1 locus and 14%
of the TSC2 locus were covered by <10 reads (Additional
file 1: Table S1), and included part of TSC2 exon 34
(chr16: 2134380–2134393) and part of TSC1 exon 10
(chr9: 135786880–135787089). For these regions it is
possible that germ-line mutations were missed.
To try and identify regions showing possible copy
number variations we calculated z-scores for all the se-
quenced fragments in the target regions, but did not find
evidence for large (>150 basepair) deletions or other re-
arrangements in the 7 TSC NMI individuals.
TSC1 locus
We identified between 0 and 74 heterozygous SNPs, as
listed in dbSNP132, across the TSC1 locus per individual
(mean >33 SNPs per individual), and between 3 and 25
SNPs homozygous for the minor allele (mean >15 per
individual) (Additional file 1: Table S3A). Furthermore,
we identified between 1 and 7 InDel variants (mean 3
per individual), as listed in dbSNP132, and identified 4
variants that were not listed in dbSNP132 but had beenFigure 1 Coverage expressed as number of reads (forward + reverse)
covered; coverage was inadequate for bases where the number of reads wreported in the GoNL database [20]. In addition to the
variants listed in dbSNP132 and the GoNL database, we
identified 6 variants that had been identified previously
in 3 of the 7 individuals by conventional molecular test-
ing, but had been excluded as being disease-causing. All
of the TSC1 variants identified by previous molecular
testing were confirmed by the HaloPlex data. In 4 indi-
viduals, previous molecular tests had not identified any
TSC1 variants. Finally, we identified 10 variants that had
not, to our knowledge, been reported previously. We
considered these “new” variants as candidate TSC-
causing mutations (see below).
TSC2 locus
Across the TSC2 locus we identified between 2 and 40
heterozygous SNPs per individual(mean >18 SNPs per in-
dividual), between 0 and 19 SNPs homozygous for the
minor allele (mean >4 per individual), and between 0 and
5 InDel variants (mean >2 per individual) (Additional
file 1: Table S3B). In addition, 2 variants listed in the
GoNL database were identified. Previous molecular testing
had identified 21 SNPs and 10 InDels in 4 of the indi-
viduals tested. All these variants had been excluded as
being disease-causing. All of the TSC2 variants identi-
fied by previous molecular testing were confirmed by
the HaloPlex data. In 3 individuals, previous molecular
tests had not identified any TSC2 variants. We identi-
fied 13 “new” TSC2 variants that had not, to our know-
ledge, been reported previously and that we considered
as potential TSC-causing mutations (see below).
Individual I
Individual I was diagnosed with definite TSC on the
basis of cardiac rhabdomyoma, hypomelanotic macule
and cortical tuber (Table 1). Clinical examination of the
parents did not reveal signs of TSC. We identified 4
“new” variants from the TSC1 locus and 5 “new” variants
from the TSC2 locus in DNA from individual I (Table 2).per base. Bases with >100 reads were considered to be adequately
as <10. a. TSC1; b. TSC2.
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TSC2 variants by Sanger sequencing. In each case the
variant was also detected in DNA from one of the individ-
ual’s parents (Table 2). One variant, TSC1 c.738-3539A>G
(intron 8; chr9 g.135791383T>C), was predicted to create
a new splice acceptor site. However, we were unable to
detect any abnormal TSC1 splice products by RT-PCR
analysis of RNA isolated from cultured skin fibroblasts
of individual I (data not shown). No effects on splicing
were predicted for the other “new” variants.We could
not confirm the presence of 2 TSC2 variants, either by
PCR followed by Sanger sequencing, or by allele-
specific PCR (Table 2). The TSC2 c.2545+591C>G (in-
tron 22; chr16 g.2124981C>G) change was identified in
2/10 reads using the BWA tool, and in 4/12 reads using
NIMBUS. The same variant was identified at a similar
frequency in the other 6 individuals tested, and maps to
a region consisting of seven 29 base pair repeats, mak-
ing HaloPlex capture as well as alignment and variant
calling challenging. The TSC2 c.3814+19dup (intron 31;
chr16 g.2131816insC) change was identified in 54/305
reads (18%) using BWA and 18/437 reads (4%) with
NIMBUS. For the other individuals tested, between 0%
and 6% of the reads at this position had the same inser-
tion, possibly due to stuttering of the polymerase over
the adjacent poly G stretch. We concluded that the
TSC2 c.2545+591C>G and TSC2 c.3814+19dup vari-
ants were most likely artefacts of the NGS procedure,
and unlikely to be the causative mutation in individual
I. No effects on splicing were predicted for either vari-
ant. We consider it unlikely that any of the other vari-
ants identified in DNA from individual I (Table 2) are
pathogenic mutations.
Individual II
Individual II was diagnosed with definite TSC on the basis
of cardiac rhabdomyoma, hypomelanotic macules, angio-
myolipoma, subependymal nodules and cortical tubers
(Table 1). No clinical data was available for the individual’s
parents, but the mother was reported to have TSC. One
sibling had died at birth due to the presence of cardiac
rhabdomyoma, and hypomelanotic macules and cortical
tubers were reported in another, younger sibling. We iden-
tified 5 variants mapping to TSC1 intron 20 in individual
II: a “new” variant, TSC1 c.2625+367A>G and 4 SNPs,
rs36000704 (TSC1 c.2625+383dup), rs2284902 (TSC1
c.2625+572A>G), rs200047376 (TSC1 c.2625+687dup)
and rs6597584 (TSC1 c.2625+675T>G)(Table 2). We
performed PCR followed by Sanger sequencing to con-
firm the presence of these variants in DNA from indi-
vidual II, individual II’s younger sibling and their parents.
We could not confirm the TSC1 c.2625+383dup SNP
(rs36000704) because we were unable to obtain satisfac-
tory Sanger sequence data due to the presence of anextensive polyA:T tract. SNPs rs2284902, rs6597584,
rs200047376 and rs150221955 were present in the
father and both children, while the TSC1 c.2625+367A>G
variant was present in DNA from the mother and both
children. This variant was predicted to create a new
splice donor site. However, we did not have access to
any RNA samples from this family. Therefore, we clas-
sified the TSC1 c.2625+367A>G change as a variant of
uncertain clinical significance.Individual III
Individual III was diagnosed with TSC on the basis of
angiomyolipoma, renal cysts, cardiac rhabdomyoma, fa-
cial angiofibroma, hypomelanotic macule, subependymal
nodules and cortical tubers (Table 1). No signs of TSC
were reported in the parents. The SAMtools-based vari-
ant caller identified SNP rs45464800 (TSC2 exon 16
c.3099, chr16 g.2129165) as heterozygote in individual
III. Closer inspection of the sequence data at this pos-
ition revealed 984 (BWA) or 1078 (NIMBUS) reads with
a C and 103 (BWA) or 110 (NIMBUS) reads with a G.
The TSC2 c.3099C>G change creates a new stop codon,
resulting in premature termination of the TSC2 open
reading frame (p.Y1033*). To confirm the presence of
the TSC2 c.3099C>G change in DNA from individual III,
we performed standard PCR followed by Sanger sequen-
cing as well as allele-specific PCR amplification. Sanger se-
quencing was inconclusive. Although differences in the C:
G peak ratios were detected in the sequence traces from
individual III compared to either parent, they were not
considered sufficient to confirm the presence of the vari-
ant in individual III (Additional file 1: Table S4). In con-
trast, allele-specific PCR clearly revealed the presence of
the mutant allele in DNA from individual III, but not in
DNA from either parent (Figure 2a). We concluded that
the mosaic TSC2 c.3099C>G (p.Y1033*) change was the
pathogenic mutation in individual III.Individual IV
Individual IV was diagnosed with TSC due to angiomyo-
lipoma, cardiac rhabdomyoma, retinal phakoma, facial
angiofibroma, hypomelanotic macules, subependymal
nodules, subependymal giant cell astrocytoma and cor-
tical tubers (Table 1). Clinical examination of the parents
did not reveal signs of TSC. We identified one “new”
heterozygous TSC1 variant and 6 “new” heterozygous
variants in TSC2. One of these, TSC2 c.225+2T>A
(chr16 g.2100489T>A) was predicted to destroy the
splice donor site at the 3′ end of exon 3. This change
was not detected in DNA from individual IV’s parents
and we concluded that this was the pathogenic mutation
in individual IV.
Figure 2 Allele-specific amplification of TSC2 mosaic variants.
a. Allele-specific amplification of the TSC2 c.3099C>G (p.Y1033*) mosaic
variant. Specific amplification of the mutant c.3099G (upper panel) and
normal c.3099C (lower panel) alleles from DNA from an unrelated
healthy individual (control), DNA from individual III (III), both parents,
and an individual with TSC heterozygous for the TSC2 c.3099C>G (p.
Y1033*) pathogenic variant (c.3099C/G). b. Allele-specific amplification
of the TSC2 c.2838-122G>A mosaic variant. Specific amplification of the
mutant c.2838-122A (upper panel) and normal c.2838-122G (lower
panel) alleles from DNA from an unrelated healthy individual (control),
individual VI (VI) and both parents. c. RT-PCR of TSC2 mRNA from
individual VI (VI) and 5 unrelated individuals (controls). An extra
splice variant was amplified from RNA from individual VI (arrow),
but not from the controls. d. Sequence of the additional RT-PCR
product identified in individual VI (see Figure 2c, arrow). Sequences
derived from exons 25 and 26 are in capitals; the premature stop
codon is underlined. e. PCR amplification of the TSC2 c.226-1086del10
(intron 3; chr16 g.2102256del10) variant (rs140492671) from DNA from
individuals IV and VII, the parents of individual IV and DNA from an
unrelated healthy individual (control).
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Individual V was diagnosed with TSC on the basis of
hypomelanotic macules, subependymal nodules, cortical
tubers and a possible renal angiomyolipoma (Table 1). No
signs of TSC were found in the parents, but epilepsy was
reported in a paternal cousin of the mother. We identified
2 “new” variants at the TSC1 locus: a 7 bp deletion 206 bp
upstream of TSC1 exon 1 (TSC1 c. -15894_-15888del-
TATGAGT; chr9 g.135820146delACTCATA) and a chr.9
g.135763459T>A substitution downstream of TSC1 exon
23 (Table 2). The presence of both variants in DNA from
individual V and individual V’s mother was confirmed by
Sanger sequencing. Neither variant was detected in DNA
from individual V’s father. The TSC1 c. -15894_-15888del-
TATGAGT deletion destroys a putative MYB transcrip-
tion factor binding site within the region of maximal
TSC1 promoter activity [21]. Previously, we identified a
TSC1 c.-16116_-15364del753 mutation in an individual
with TSC [13]. Although both deletions affect the same
core promoter region, individual V’s mother, who carries
the TSC1 c.-15894_-15888delTATGAGT variant, had no
signs of TSC. No RNA or additional DNA samples were
available from this family and in the absence of any other
findings, we consider the TSC1 c.-15894_-15888delTAT-
GAGT deletion to be a variant of uncertain clinical
significance.
Individual VI
Individual VI was diagnosed with TSC on the basis of bi-
lateral, multiple renal angiomyolipoma, facial angiofi-
broma, hypomelanotic lesions, cardiac rhabdomyoma,
subependymal nodules and subcortical tubers. Clinical
examination of the parents did not reveal signs of TSC.
A TSC2 c.2838-122G>A (chr16 g.2127477G>A) change
was identified in ~12% of the sequence calls at this
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reads A, 151 reads G) in DNA from individual VI. The
TSC2 c.2838-122G>A change was predicted to create a
new splice acceptor site 120 bases upstream of the alter-
natively spliced TSC2 exon 26 [22]. To confirm the pres-
ence of the TSC2 c.2838-122G>A change in DNA from
individual VI, we performed Sanger sequencing as well
as allele-specific PCR. Sanger sequencing was inconclu-
sive. Although differences in the G:A peak ratios were
detected in the sequence traces from individual VI com-
pared to either parent, they were not considered suffi-
cient to confirm the presence of the variant in individual
VI (Additional file 1: Table S4). In contrast, allele-
specific PCR clearly revealed the presence of the variant
in DNA from individual VI, but not in DNA from either
parent (Figure 2b). To investigate whether the identified
change affected splicing, RT-PCR was performed on
RNA isolated from skin fibroblasts from individual VI.
Compared to control samples, an additional PCR prod-
uct was amplified from RNA from individual VI (Fig-
ure 2c). Sequence analysis revealed that this product
contained an insertion of the 120 nucleotides immediately
upstream of exon 26, resulting in premature truncation of
the TSC2 open reading frame (Figure 2d). We con-
cluded that the mosaic TSC2 c. 2838-122G>A change
was most likely responsible for TSC in individual VI.
Individual VII
Individual VII was diagnosed with TSC on the basis of
hypomelanotic macules, facial angiofibroma, tooth en-
amel defects, brain white matter abnormalities detected
by radiology and an affected child with subependymal
nodules, cortical tuber, cardiac rhabdomyoma and hypo-
melanotic macules (Table 1). We identified 4 “new”
variants in TSC2, in introns 14 (c.1443+71A>G, chr16
g.2113125A>G; c.1443+410C>T, chr16 g.2113464C>T),
17 (c.1839+206C>T, chr16 g.2120785C>T) and 30
(c.3610+319G>A, chr16 g.2130697G>A). In addition, 4
variants (in introns 3 and 5) were identified where the
allelic ratio was skewed (minor allele detected in <40%
or >60% of the sequence reads) (Table 2). For 3 of
these, the presence of both alleles in DNA from indi-
vidual VII was confirmed by PCR followed by Sanger
sequencing. The remaining variant (rs140492671; TSC2
c.226-1086delTTGTCTGAAT (intron 3), chr16 g.2102256-
2102266delTTGTCTGAAT) was identified in 10% of
the reads. Individual IV (see above) was homozygous
for rs140492671. To confirm the presence of rs140492671
in DNA from individuals IV and VII, we performed PCR
followed by Sanger sequencing. In individual VII, PCR re-
vealed a larger than expected ~450 bp product in addition
to the expected ~190 bp product. DNA from individual
IV and individual IV’s father showed only the ~450 bp
product, while PCR of DNA from individual IV’s motherrevealed both bands (Figure 2e). Sequence analysis of
the ~190 bp product from individual IV’s mother and
control DNA samples, revealed the normal sequence.
Nucleotides 2102256–2102266 were not deleted. Se-
quence analysis of the ~450 bp band from individuals
IV, VII and individual IV’s parents revealed the pres-
ence of a 338 bp insertion consisting of an Alu repeat
flanked by two direct 18 bp repeat sequences (5′-
AAGAGTATTGTCAATGAG-3′). A de novo TSC2 c.225
+2T>A mutation was identified in individual IV (see
above); therefore the presence of the Alu insertion in indi-
vidual IV and both unaffected parents indicates that it is
unlikely to cause TSC in indiviual VII. In conclusion, we
identified 4 variants of uncertain clinical significance in
DNA from individual VII, but failed to identify a good
candidate TSC1 or TSC2 mutation. It is possible that we
missed a mosaic mutation in individual VII. A DNA sam-
ple from the affected child of individual VII has been re-
quested. Analysis of this sample might help identify the
causative mutation in this family.
Conclusions
Identification of a TSC1 or TSC2 mutation is sufficient for
a diagnosis of TSC and provides individuals and families
affected by TSC with clarity regarding their risk of devel-
oping symptoms, or of having an affected child. To in-
crease the yield of TSC1 and TSC2 mutations identified in
the TSC patient population we applied a targeted NGS
strategy to assess the TSC1 and TSC2 loci in 7 TSC NMI
individuals. In total, we identified and confirmed 19
“new” variants (Table 2). These have all been submitted
to the TSC1 and TSC2 Leiden Open Variation Databases
(http://chromium.liacs.nl/LOVD2/TSC/home.php). Sequence
analysis of the TSC1 and TSC2 genomic loci in a larger co-
hort of individuals with TSC could help establish whether
any of these changes are disease-causing or are more likely
to be rare, benign variants. In addition, functional studies
could help determine whether the variants affect TSC1
or TSC2 expression. The availability of patient-
derived cells for RNA-based studies would greatly
facilitate these studies. In addition, DNA from both
biological parents and other family members
(affected and unaffected) will be helpful for estab-
lishing pathogenicity. We identified “new” variants
in all individuals tested, and it is likely that many
other individuals will carry other new variants of un-
certain clinical significance. In the absence of an ob-
vious candidate pathogenic mutation, it will be even
more important to be able to perform functional
studies that can distinguish pathogenic and benign
variants.
We failed to validate 4 variants. In 2 cases (TSC2
c.2545+591C>G and c.3814+19dup; individual I) we
concluded that these were miscalls in regions with low
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presence of a polyA:T tract made confirmation with
Sanger sequencing impossible; and in the final case
(rs140492671; individuals IV and VII), there was a dis-
crepancy between the HaloPlex data and the PCR and
Sanger sequencing results.
For the TSC1 locus we obtained >90% coverage at a
read-depth >10 (Additional file 1: Tables S1 and S2)
and identified 21–91 variants per individual (Additional
file 1: Table S3A). In individual I and the unaffected
mother, we identified a substitution in intron 8 (TSC1
c.738-3539A>G) that was predicted to create a new 3′
splice site. However, we did not identify abnormal
splice products in RNA from individual I. In individual
II and the affected sibling and mother, we identified a
novel TSC1 c.2625+367A>G variant in intron 20 that
was predicted to create a new 5′ splice site. Unfortu-
nately, we were unable to investigate whether this vari-
ant affects splicing of the TSC1 mRNA and the clinical
significance of the variant remains uncertain, even
though it cosegregated with TSC. In individual V and
the unaffected mother, we identified a 7 bp deletion in
the TSC1 promoter (TSC1 -15894_-15888delTATGAGT)
that affects a predicted binding site for c-MYB [21]
(http://alggen.lsi.upc.es/). c-MYB has been found to inter-
act with the TSC1 promoter, as well as the TSC2 and
TBC1D7 promoters [23], and although it is predominantly
expressed in hematopoietic cells, other tissues, such as
skin, are known to express c-MYB (http://www.ebi.ac.uk/
gxa/genes/ENSG00000118513). It will be important to es-
tablish whether the 7 bp deletion affects TSC1 expression.
However, in the absence of additional clinical or func-
tional findings, we have not yet been able to classify this
variant.
Over 86% of the TSC2 locus was covered by 10 or
more reads (Additional file 1: Tables S1 and S2) andFigure 3 Pie charts showing the diagnostic yield in individuals with T
TSC1 or TSC2 mutation (TSC mutation), an unclassified variant (UV) or no m
molecular testing in individuals with definite TSC [12]. b. Results of targeted
after conventional molecular testing (this study).10–46 variants were identified per individual (Additional
file 1: Table S3B). In individual IV we identified a de novo
splice site mutation in intron 2 (TSC2 c.225+2T>A) that
had been missed during the original screening procedure.
Other examples of TSC NMI individuals with germline,
exonic mutations that have been missed by conventional
molecular screening have been described previously [10].
In 2 individuals we detected mosaic TSC2 mutations. In
individual III a TSC2 c.3099C>G (p.Y1033*) mutation was
identified in 10% of the corresponding sequence reads,
and in individual VI a novel TSC2 c.2838-122G>A variant
was identified in 12% of the corresponding sequence
reads. The TSC2 c.2838-122G>A variant was predicted to
create a new splice acceptor site, 120 nucleotides up-
stream of the normal exon 26 acceptor site. RT-PCR
analysis of RNA isolated from skin fibroblasts of indi-
vidual VI revealed the presence of an additional splice
product (Figure 2c) and sequence analysis confirmed
the insertion of 120 nucleotides, resulting in a prema-
ture stop codon (Figure 2d). The presence of both vari-
ants was confirmed by allele-specific PCR (Figures 2a
and b), but neither variant could be reliably detected
with a standard PCR-Sanger sequencing approach
(Additional file 1: Table S4). We selected TSC NMI in-
dividuals with clinically definite TSC. Therefore our co-
hort is not representative of the TSC NMI population
as a whole [7,12]. Nonetheless, we note that both indi-
viduals with a mosaic TSC2 mutation had TSC with
multiple organ involvement, but mild or no intellectual
disability.
We did not obtain equal or optimal coverage of the en-
tire TSC1 and TSC2 genomic regions. Coverage varied
from 0 to >1000 calls per nucleotide. It is possible that
in regions with <100 calls per nucleotide we missed
mosaic mutations and that in low coverage regions
(<10 calls per nucleotide) we also missed germ-lineSC. Percentages of individuals with definite TSC and a pathogenic
utation identified (NMI) are indicated. a. Results of conventional
NGS of the TSC1 and TSC2 loci in individuals classified as TSC NMI
Nellist et al. BMC Medical Genetics  (2015) 16:10 Page 10 of 11mutations. We are now working on improving our de-
sign, to utilise longer reads and alternative HaloPlex
probe sets to obtain higher overall coverage and, specif-
ically, higher coverage of the coding sequences. In
addition, analysis of patient DNA from other easily ac-
cessible tissue sources, such as buccal or skin cells,
might be useful to help identify mutations that are only
present in a subset of somatic cells.
In summary, we screened 7 TSC NMI individuals
using a HaloPlex custom capture NGS approach. In in-
dividual IV we identified a germ-line mutation that had
been missed by previous mutation analysis screens; in
individuals III and VI we identified and verified mosaic
mutations; and in individuals I, II, V and VI we identified
variants of uncertain clinical significance. In individual
VI the mutation was located outside the region screened
in our standard protocol. In total, we confirmed patho-
genic mutations in 3/7 (43%) TSC NMI individuals
(Figure 3), indicating that targeted NGS of the TSC1 and
TSC2 loci is a useful technique for the identification
of otherwise difficult to detect TSC1 and TSC2 muta-
tions in individuals with TSC. The challenge will be to
ensure that targeted NGS-based detection is also a cost-
effective alternative for mutation screening in TSC. Cur-
rently we have a cohort of >40 TSC NMI individuals in
whom we would like to perform targeted NGS of the
TSC1 and TSC2 loci. We predict that the implementa-
tion of this technique in routine DNA diagnostic screens
will result in an increased yield of TSC1 and TSC2 mu-
tations in individuals with TSC.
Additional file
Additional file 1: Table S1. Overview of low coverage regions for
Haloplex targeted genomic sequencing of the TSC1 and TSC2 loci.
Table S2. Haloplex custom capture targeted sequencing reads mapped
to the TSC1 and TSC2 loci using NIMBUS and standard BWA alignment.
Table S3. Overview of Haloplex targeted genomic sequencing of the
TSC1 and TSC2 loci. Table S4. Peak ratios Sanger sequencing.
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